FB Pixel

601.948.8005

Call Now For A Free Consultation

Facebook

Twitter

Se Habla Español

Zantac Cancer

Chhabra & Gibbs, P.A. > Blog Posts  > Zantac Cancer

Dispatches from the Zantac MDL

Zantac MDL

All Zantac cases filed in federal court are now before Judge Rosenberg in the Southern District of Florida (“MDL Court”). To date, the Court has entered 42 pretrial orders covering everything from appointing lead counsel and leadership committees for Plaintiffs and Defendants to establishing a procedure lawyers can use to register the claims of their unfiled clients rather than filing formal complaints. Below are some of the highlights of the 42 pretrial orders (“PTO”). We’ll be posting information about the Zantac litigation on a regular basis, so check back often to stay up to date. PTO 11:   Establishing a procedure for...

Continue reading

Recall on Zantac

zantac recall

Our Partner Firm, Chhabra Gibbs & Herrington PLLC, wrote about the recent Zantac recall and how the FDA has decided to pull all of the Zantac product off the shelf due to NDMA and cancer from contamination: The heartburn and ulcer medication Zantac, also known as Ranitidine, which belongs to the histamine-2 blockers category, has been recalled by the FDA.   The FDA has been investigating Zantac for a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications.  The FDA has determined that the impurity increases over time and when stored at higher than room temperatures, that impurity exposes consumers to an unacceptable level of it....

Continue reading

Zantac And Cancer Lawsuits

zantac cancer

Zantac, or its generic form Ranitidine, is used to treat and prevent the formation of ulcers in the stomach and counteract the accumulation of acid in the stomach that may lead to gastroesophageal reflux disease (GERD). Recently, the U.S. Food and Drug Administration (FDA) alerted the public that some ranitidine medications, including Zantac, contain low levels of a possible human carcinogen known as N-nitrosodimethylamine (NDMA). The FDA is currently assessing the risk posed to patients from the presence of NDMA. This compound is classified as a potentially dangerous cancer-causing agent, and is used in gasoline, rocket fuel, as a stabilizer in...

Continue reading
Translate »